



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 4919

<b>SERIAL NUMBER</b> 09/704,306	<b>FILING DATE</b> 11/02/2000 <b>RULE</b>	<b>CLASS</b> 514	<b>GROUP ART UNIT</b> 1614	<b>ATTORNEY DOCKET NO.</b> PH-7032
<b>APPLICANTS</b> James P. Beck, Kalamazoo, MI; Mark A. Smith, Landenberg, PA;				
** CONTINUING DATA ***** THIS APPLN CLAIMS BENEFIT OF 60/163,270 11/03/1999				
** FOREIGN APPLICATIONS *****				
IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 03/21/2001				
Foreign Priority claimed <input type="checkbox"/> yes <input checked="" type="checkbox"/> no 35 USC 119 (a-d) conditions <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> not after met <input checked="" type="checkbox"/> Allotment		<b>STATE OR COUNTRY</b> MI	<b>SHEETS DRAWING</b>	<b>TOTAL CLAIMS</b> 49
Verified and Acknowledged <i>Bunde Calerman AC</i> Examiner's Signature Initials			<b>INDEPENDENT CLAIMS</b> 1	
<b>ADDRESS</b> Peter L. Dolan DuPont Pharmaceuticals Company c/o E I duPont de Nemours and Company 1007 Market Street Wilmington, DE 19898				
<b>TITLE</b> Novel 4-phenyl substituted tetrahydroisoquinolines and use thereof				
<b>FILING FEE RECEIVED</b> 1362	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue ) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit _____	

8C  
3-21-04